



UNIVERSITY  
OF TAMPERE

This document has been downloaded from  
TamPub – The Institutional Repository of University of Tampere

 *Publisher's version* <http://urn.fi/URN:NBN:fi:uta-201508272256>

Author(s): Kontro, Heidi; Cannino, Guiseppa; Rustin, Pierre; Dufour, Eric;  
Kainulainen, Heikki  
Title: DAPIT Over-Expression Modulates Glucose Metabolism and Cell  
Behaviour in HEK293T Cells  
Year: 2015  
Journal Title: Plos ONE  
Vol and number: 10 : 7  
Pages: 1-20  
ISSN: 1932-6203  
Discipline: Biomedicine  
School /Other Unit: BioMediTech; School of Medicine  
Item Type: Journal Article  
Language: en  
DOI: <http://dx.doi.org/10.1371/journal.pone.0131990>  
URN: URN:NBN:fi:uta-201508272256  
URL: <http://dx.doi.org/10.1371/journal.pone.0131990>

All material supplied via TamPub is protected by copyright and other intellectual property rights, and duplication or sale of all part of any of the repository collections is not permitted, except that material may be duplicated by you for your research use or educational purposes in electronic or print form. You must obtain permission for any other use. Electronic or print copies may not be offered, whether for sale or otherwise to anyone who is not an authorized user.

RESEARCH ARTICLE

# DAPIT Over-Expression Modulates Glucose Metabolism and Cell Behaviour in HEK293T Cells

Heidi Kontro<sup>1</sup>, Giuseppe Cannino<sup>2</sup>, Pierre Rustin<sup>3,4</sup>, Eric Dufour<sup>2</sup>, Heikki Kainulainen<sup>5\*</sup>

**1** Tampere Centre for Child Health Research, University of Tampere, Tampere, Finland, **2** Institute of Biomedical Technology, University of Tampere, Tampere, Finland, **3** INSERM UMR 1141, Paris, France, **4** Université Paris 7, Paris, France, **5** Department of Biology of Physical Activity, University of Jyväskylä, Jyväskylä, Finland

\* [heikki.s.o.kainulainen@ju.fi](mailto:heikki.s.o.kainulainen@ju.fi)



OPEN ACCESS

**Citation:** Kontro H, Cannino G, Rustin P, Dufour E, Kainulainen H (2015) DAPIT Over-Expression Modulates Glucose Metabolism and Cell Behaviour in HEK293T Cells. PLoS ONE 10(7): e0131990. doi:10.1371/journal.pone.0131990

**Editor:** Mauro Salvi, University of Padova, ITALY

**Received:** July 10, 2014

**Accepted:** June 9, 2015

**Published:** July 10, 2015

**Copyright:** © 2015 Kontro et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** The study was financially supported by the Competitive Research Funding of the Pirkanmaa Hospital District grant 9G030, HKo; Finnish Cultural Foundation, Pirkanmaa Regional fund, HKo; Finnish Diabetes Research Foundation, HKo; Academy of Finland, HKA; Finnish Cultural Foundation Central Fund, HKA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The URLs of funding sources are as follows in the order they are mentioned: <http://www.pshp.fi/default.aspx?nodeid=10066&contentlan=2>, <https://www.skr.fi/en/finnish->

## Abstract

### Introduction

Diabetes Associated Protein in Insulin-sensitive Tissues (DAPIT) is a subunit of mitochondrial ATP synthase and has also been found to associate with the vacuolar H<sup>+</sup>-ATPase. Its expression is particularly high in cells with elevated aerobic metabolism and in epithelial cells that actively transport nutrients and ions. Deletion of DAPIT is known to induce loss of mitochondrial ATP synthase but the effects of its over-expression are obscure.

### Results

In order to study the consequences of high expression of DAPIT, we constructed a transgenic cell line that constitutively expressed DAPIT in human embryonal kidney cells, HEK293T. Enhanced DAPIT expression decreased mtDNA content and mitochondrial mass, and saturated respiratory chain by decreasing H<sup>+</sup>-ATP synthase activity. DAPIT over-expression also increased mitochondrial membrane potential and superoxide level, and translocated the transcription factors hypoxia inducible factor 1 $\alpha$  (Hif1 $\alpha$ ) and  $\beta$ -catenin to the nucleus. Accordingly, cells over-expressing DAPIT used more glucose and generated a larger amount of lactate compared to control cells. Interestingly, these changes were associated with an epithelial to mesenchymal (EMT)-like transition by changing E-cadherin to N-cadherin and up-regulating several key junction/adhesion proteins. At physiological level, DAPIT over-expression slowed down cell growth by G1 arrest and migration, and enhanced cell detachment. Several cancers also showed an increase in genomic copy number of *Usmg5* (gene encoding DAPIT), thereby providing strong correlative evidence for DAPIT possibly having oncogenic function in cancers.

### Conclusions

DAPIT over-expression thus appears to modulate mitochondrial functions and alter cellular regulations, promote anaerobic metabolism and induce EMT-like transition. We propose

[cultural-foundation/regional-funds/pirkanmaa-regional-fund](http://cultural-foundation/regional-funds/pirkanmaa-regional-fund), <http://www.diabetestutkimus.fi/en>, <http://www.aka.fi/en-GB/A/Funding-and-guidance/Funding/>, <https://www.skr.fi/en/grants>.

**Competing Interests:** The authors have declared that no competing interests exist.

that DAPIT over-expression couples the changes in mitochondrial metabolism to physiological and pathophysiological regulations, and suggest it could play a critical role in H<sup>+</sup>-ATP synthase dysfunctions.

## Introduction

DAPIT is a 58 amino acid peptide first discovered in insulin-sensitive tissues of the streptozotocin-diabetic rat model [1]. It is a component of the F<sub>o</sub> subunit of the mitochondrial H<sup>+</sup>-ATP synthase (F-ATPase) [2–4] and its knock-down results in the loss of this enzyme [5]. Recently we found that DAPIT is also a component of the vacuolar proton pump (V-ATPase) [6].

The gene encoding DAPIT is *Usmg5* that is well conserved from insects to vertebrates underlining its potentially important function. A histological analysis of DAPIT in rat and human tissues revealed an elevated expression in cells with a high aerobic metabolism and in epithelial cells involved in the active transport of nutrients and ions [6].

Interestingly, DAPIT expression appears to be modulated in various disease models. Streptozotocin (STZ) induction of diabetes in rats caused a down-regulation of DAPIT mRNA in insulin-sensitive tissues [1], but it increased DAPIT protein levels, suggesting post-transcriptional regulation [6]. In diabetic neuropathies, hyperglycaemia up-regulates the DAPIT protein in the Schwann cells of neonatal rats [7]. DAPIT is also enriched in the brain synaptosomes of a murine model of Parkinson's disease [8]. In addition, Gene Expression Omnibus [GEO] database [9] screening suggests that the *Usmg5* transcript is up-regulated in various cancers (GEO accession GDS1792 [10], GDS3330 [11], GDS3754 [12], GDS2755 [13]), in adipose tissue of high weight gainers (GDS 2319 [14]) and in cardiac deficiencies (GDS487, GDS696); but, since post-transcriptional regulations seem to play an important role in DAPIT synthesis, it is difficult to estimate the consequences this upregulation could have at the functional level.

As a component of the H<sup>+</sup>-ATP synthase, DAPIT is involved in mitochondrial oxidative phosphorylation (OXPHOS), which is the major source of ATP in aerobic organisms. In various diseases, including cancer, diabetes, cardiopathies and degenerative diseases, metabolic stress lead to changes in OXPHOS activity and properties, altering mitochondrial parameters such as respiration, membrane potential, ATP production, ROS generation and mitochondrial mass. Such changes can be either beneficial (partly complementing the defects caused by the disease) or detrimental (precipitating its pathological consequences). In addition, changes in OXPHOS activity are known to elicit retrograde regulations, further altering the cellular metabolism. For example, tumour cells shift from oxidative ATP generation to glycolytic production of energy, even under normoxic conditions (the so-called Warburg effect) [15,16]. A key regulator of this effect is the nuclear stabilization of hypoxia-inducible factor 1 $\alpha$  (Hif1 $\alpha$ ). Hif1 signalling up-regulates glycolysis and controls mitochondrial function, cell proliferation and angiogenesis while repressing apoptosis [15,17]. Hif1 $\alpha$  activation usually requires hypoxia, but it is also observed in normoxic conditions in response to increased mitochondrial ROS production and/or accumulation on tricarboxylic acid cycle (TCA) intermediates [18,19]. Changes in respiratory chain function can also be sensed by mitochondrial sirtuins (Sirt 3–5) that modulate the activity of metabolic enzymes via protein deacetylation or mono-ADP-ribosylation [20]. In particular, Sirt3, a NAD<sup>+</sup>-dependent deacetylase is able to activate many protein targets, including respiratory chain complex I, acetyl-CoA synthetase 2 and glutamate dehydrogenase, leading to enhanced function of TCA and increased respiration [21,22].

As *Usmg5* mRNA or DAPIT is up-regulated in various diseases and metabolic disorders known to be associated with mitochondrial functions, we aimed to study the effects of DAPIT over-expression at the cellular level. DAPIT was stably transfected into human embryonic kidney cells, HEK293T, and we studied cell morphology-, mitochondria-, nuclei-, cell junction-, behaviour- and metabolism-related parameters. We show that DAPIT over-expression modulates mitochondrial activity causing a cellular regulation that promote glycolysis and induce EMT-like transition.

## Materials and Methods

### Plasmid DNA constructs

The full-length DAPIT cDNA was originally cloned in pCR-TOPO vector (Invitrogen, Carlsbad, CA, USA) [1]. The DAPIT coding sequence—including ten nucleotides from the 5' NCR—was recloned by PCR with the pEGFP sequence of the pIRES2-EGFP vectors (Clontech Laboratories, Palo Alto, CA, USA). The primers used were 5'- acgaattcgattgaagtcattgctggccca -3' and 5'- tcgggatccttatgttgctttcacagctggggg -3'. The PCR reactions consisted of cycles at 96°C for 2 min, 4x (96°C for 30 s, 50°C for 1 min, 72°C for 30 s), 25x (96°C for 30 s, 60°C for 1 min, 72°C for 30 s) and 72°C for 10 min. The DAPIT amplicon was purified, cloned into the pIRES2-EGFP vector with *EcoRI* and *BamHI* restriction enzymes (MBI Fermentas GmbH, Leon-Rot, Germany; Clontech Laboratories, Palo Alto, CA, USA) and amplified in One Shot TOP 10 bacteria (Invitrogen). The insert size (~204 bp) was confirmed by restriction enzyme digestion, and the insert DNA was fully sequenced. The construct was used for stable transfection of HEK293T cells.

### Cell culture, transfections and RT-PCR

HEK293T cells (ATCC, crl-3216) were cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich, Ayshire, UK or Gibco BRL, Paisley, Scotland, UK), containing 4.5 g/l of D-glucose, 10% foetal calf serum (Sigma), 50 µg/ml uridine, 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U penicillin and 100 µg/ml of streptomycin (Gibco BRL) at 37°C in an incubator with 5% CO<sub>2</sub>. Transfections were performed using Lipofectamine according to the manufacturer's protocol (Invitrogen). Transfection efficiency was estimated by flow cytometry using GFP fluorescence. Twenty-five Geneticin-resistant clones (Calbiochem/Merck KGaA, Darmstadt, Germany; 2 mg/ml) were selected and combined to form the polyclonal cell line. Total RNAs from pIRES2-EGFP and DAPIT-pIRES2-EGFP stably transfected cells were extracted by RNeasy Mini Kit (Qiagen), and 1 µg total RNA was used for RT-PCR using M-MuLV reverse transcriptase, as suggested by the provider (MBI Fermentas). The obtained cDNAs of control and transgenic cells were multiplied by PCR as indicated above.

### Fluorescence microscopy

For live imaging of mitochondria and lysosomes, the cells grown on poly-L-lysine coated cover slips (Sigma) were washed with PBS and incubated in a medium containing 100 nM Mito-tracker Red (Invitrogen) or 100 nM LysoTracker red (Invitrogen) for 10–30 min at 37°C. Mito-tracker-stained cells were PBS washed and maintained in DMEM medium for 1 hour at 37°C before observation. For immunofluorescence microscopy, cells fixed in 4% paraformaldehyde (Sigma) for 15 min were permeabilized with 0.5% Triton X-100 (MP Biomedicals, Illkirch, France) in TBS (10mM Tris, 0.9% NaCl, pH 8.0 (Sigma)) for 10 min. Non-specific epitopes were blocked by using 5% w/v non-fat milk powder, 2% w/v BSA (Sigma) for 30 min. Samples were incubated in TBS-T (TBS with 0.1% Tween (Sigma)) with the primary antibody (αD15C,

1:300) [5] for 2 h at room temperature, washed for 3x5min and incubated in Alexa Fluor 488 or 568 goat anti-rabbit, Alexa Fluor 568 goat anti-mouse or Alexa Fluor 549 chicken anti-mouse IgG secondary antibodies (Molecular Probes, Eugene, Oregon, USA, 1:4000) for 1 hour. Coverslips were mounted on slides using Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA), and samples were examined by confocal microscopy at 100x magnification using a Perkin Elmer-Cetus/Wallac UltraView LCI system (Wellesley, MA, USA) equipped with appropriate excitation and emission filters, an Andor iXon DV885 EMCCD camera and the Andor iQ software (Andor, Belfast, UK), or with a conventional fluorescence microscope at 40x and 60x magnification (Olympus BX60, Olympus Corporation, Japan). Images were further processed using Corel Photo-Paint 11 (Corel Corporation).

### Mitochondrial copy number calculation and citrate synthase activity

For mtDNA copy-number analysis, total DNA was prepared as reported in Fukuoh et. al. [23]. The isolated DNA from  $0.4 \times 10^6$  cells were resuspended in TE buffer (pH 8.0), purified and quantified by Nanodrop. Relative mtDNA copy number was measured by real-time qPCR using primers for mitochondrial COXII subunit (Forward *cgctgtaactatcctgcccg*, Reverse *tggttaagggaggatcgttg*) and nuclear APP (Forward *ttttgtgtgctctcccaggctc*, Reverse *tggtcactggtttggc*) in a StepOnePlus instrument (Applied Biosystems) using Fast SYBR Green Master Mix (Applied Biosystems) under the manufacturer's recommended conditions, with 20 sec of enzyme activation at 95°C, followed by 40 cycles of 95°C for 3 sec and 60°C for 30 sec.

The activity of citrate synthase of cells was measured using a kit (Sigma-Aldrich, CS0720) according to the manufacturer's instructions with an automated KoneLab device (Thermo Scientific, Vantaa, Finland).

### Oxygen consumption and fluorescence biomarkers

The mitochondrial measurements in living cells were performed as in Cannino et. al. [24]. Oxygen consumption was measured with a Clark-type electrode (Oxygraph, Hansatech Instruments Ltd, Norfolk, UK). Intact cell respiration was recorded from  $1 \times 10^7$  cells suspended in 500  $\mu$ l of DMEM medium at 37°C. Maximum respiration was obtained by FCCP titration (5–9  $\mu$ M). Oxygen consumption was stopped with 150 nM rotenone, 30 ng/ml antimycin A, 100  $\mu$ M Cyanide or 100–200 nM Oligomycin (Sigma). Oxygen consumption from  $1 \times 10^7$  cells permeabilized by 80  $\mu$ g/ml digitonin was recorded in respiratory buffer A (225 mM sucrose, 75 mM mannitol, 10 mM Tris-buffer pH 7.4, 10 mM KCl, 10 mM  $\text{KH}_2\text{PO}_4$ , 5 mM  $\text{MgCl}_2$ , 1mg/ml BSA (Sigma)) at 37°C. The substrate concentrations were 10 mM ADP, 5 mM pyruvate + 5 mM malate for complex I, 10 mM succinate for complex II, and 50  $\mu$ M TMPD and 1 mM ascorbate for complex IV. All measurements were corrected by subtracting the residual oxygen consumption present after full inhibition of the respiratory chain.

For the mitochondrial mass, membrane potential and superoxide measurements, flow cytometry assays were used. In the absence of G418,  $4 \times 10^5$  (Vector) and  $4.5 \times 10^5$  (DAPIT) cells were seeded in culture medium. After overnight culture, the subconfluent cells were treated with 200 nM 10-nonyl acridine orange (NAO; Invitrogen,) for 30 min at 37°C, 200nM tetramethyl rhodamine methyl ester (TMRM; Invitrogen,) for 30 min at 37°C or 2.5  $\mu$ M MitoSox (Invitrogen,) for 45 min at 37°C. The staining was stopped by replacing the medium with 1xPBS, and cells were kept at 37°C (NAO and TMRM) or on ice (MitoSox) until measured. Negative controls for mitochondrial membrane potential were obtained by adding 10  $\mu$ M FCCP before flow cytometry analysis.

The fluorescence was counted from 40,000 cells using a BD Accuri C6 flow cytometry (BD Biosciences). The region of interest was defined by using the forward scatter/side scatter values, excluding the debris and dead cells. The staining was measured either by using 488 nm (band-pass) excitation and emission of FL2 ( $585 \pm 40$  nm) for NAO and TMRM, FL3 ( $620 \pm 15$  nm) for Mitosox and FL1 ( $533 \pm 40$  nm) for GFP. The fluorescence compensations were estimated independently for each series of experiments. All measurements provided as “relative to mitochondrial (mt) content” were normalized by NAO quantification, whereas measurements provided as “per cell” were normalized to the cell count.

### Isolation of mitochondria and complex V activity

For crude extraction of mitochondria, the cells from four  $17.5 \text{ cm}^2$  or 8–10  $10 \text{ cm}^2$  culture plates were collected by centrifugation at  $250 g$  for 3 min at room temperature. The rest of the protocol was carried out in a cold room ( $+4^\circ\text{C}$ ) on ice. The cells were bloated in 5.5 ml of hypotonic buffer (10mM NaCl, 1.5mM  $\text{MgCl}_2$ , 10mM Tris-HCl pH 7.5 (Sigma), protease inhibitor cocktail (Roche, Mannheim, Germany)) for 8–13 min, ruptured with eight strokes of teflon pestle. 4 ml of 2.5X MS buffer (700 mM sucrose, 2.5 mM EDTA, 12.5 mM Tris-HCl pH 7.5, protease inhibitors) was added. To remove nuclei and cell debris, the samples were centrifuged at  $1,300 g$  for 10 min. Mitochondria from the supernatant was pelleted by centrifugation at  $17,000 g$  for 15 min, and diluted to 0.5–1 ml of 1X MS buffer (0.28 mM sucrose, 5 mM Tris-HCl, 1 mM EDTA pH 7.5, protease inhibitors).

Fifteen ml of 1.5 M and 1.0 M sucrose in buffer (10mM Tris-HCl pH 7.4, 1 mM EGTA, 0.1% BSA, protease inhibitors) were layered in ultracentrifuge tubes. The crude extract of mitochondria was added on the top of sucrose layers and centrifuged at  $60,000 g$  for 20 min at  $4^\circ\text{C}$ . The resulting fraction of mitochondria in the interphase of sucrose layers was collected, the volume measured and slowly (15–20 min) diluted on ice for 4X with 0.2M mannitol in Tris-EGTA-BSA buffer. Finally, the mitochondria were pelleted at  $17,000 g$  for 15 min at  $4^\circ\text{C}$ , diluted to 40–50  $\mu\text{l}$  of 1X MS buffer and stored at  $-80^\circ\text{C}$ .

The oligomycin-sensitive complex V activity was spectrophotometrically measured in the backward direction using lactic dehydrogenase and pyruvate kinase as coupling enzymes, as essentially described elsewhere [25,26].

### Cell growth, mortality, and synchronization

Fifteen thousand cells were seeded on a 24-well culture plate (Nunclon, Thermo Scientific) in 500  $\mu\text{l}$  of culture medium in the presence of antibiotics (Penicillin-Streptomycin & G418). Cell proliferation and mortality were followed for five days by counting the living and dead cells in a Burkert hemocytometer after trypan blue labelling (0.4%; Sigma).

The control and DAPIT overexpressing cells were synchronized by a double thymidine block method (DIAMONDS Deliverable 1-D1.1.3, [ResearchGate.net](https://www.researchgate.net)) for more accurate follow up of cell division. At 30% confluence in 24-well culture plate, the cells were washed twice with 1x PBS and 1 ml of cell culture medium supplemented with 2 mM thymidine (Sigma) was added for 18 hours. Thymidine was washed out and the cell divisions were released by adding fresh cell culture medium for nine hours. This was followed by another thymidine step for 17 hours after which the cells progress synchronously through G2- and mitotic phase. Upon the release from the thymidine block, the cells were cultured in normal medium for 4, 8, 12, 16 and 24 hours in order to follow the cell cycle progress. At each time point the cells were collected, pelleted, stained with 250  $\mu\text{l}$  of PI staining solution (25 $\mu\text{g/ml}$  propidium iodide, 100 $\mu\text{g/ml}$  RNase A, 0.1% sodium citrate, 0.1% Triton X-100 (Sigma)) for 20 min on ice and measured by flow cytometry (488 nm excitation,  $>670$  nm emission; FL3). The number of cells (arbitrary

units) was blotted against the DNA content at each time point. The test was repeated for four times.

### Migration and adhesion

The migration was studied by scratch wound test in a 12-well culture plate (Nunclon). The cells were grown confluent, and fresh medium was provided three hours prior to starting the test. After 1 hour-treatment with 20 µg/ml Mitomycin C (Sigma) cells were scratched with a tip, washed and incubated overnight at 37°C. After fixation with 4% PFA for 15 min and PBS washing, cells were stained with crystal violet (0.5 mM) for 5 min in 70% ethanol. The cells migrating in the scratched area were counted using a phase contrast microscope (Axiovert 200 M, Zeiss). Cell attachment was studied using PMS/MTS (Promega, Madison, WI, USA) according to the manufacturer's protocol. Detachment was determined according to the protocol used in migration assays in a 48-well culture plate (Nunclon). The empty areas of detached cells in the bottom of wells were quantified by ImageJ ([imagej.nih.gov/ij](http://imagej.nih.gov/ij)) analysis.

### Western blot analysis

Proteins from subconfluent (approximately 50–70%) cells were extracted in PBS containing 1% Triton X100 and protease, followed by incubation on ice for 30 min and centrifugation at 12,000 g for 1 minute. The protocol applied by Teittinen et al. [27] was followed to obtain nuclear extracts. Briefly, subconfluent cells were washed with PBS and collected by centrifugation. The cells were resuspended in 5 ml hypotonic buffer (10 mM Hepes (pH 7.9), 10 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.5 mM DTT (Sigma)) and broken on ice using a Dounce homogenizer. Nuclei were pelleted by centrifugation (228 g, 5 min, +4°C) and purified by isopycnic centrifugation (1,430 g, 5 min, +4°C) on a two-step sucrose gradient: 250 mM sucrose, 10 mM MgCl<sub>2</sub> vs 880 mM sucrose, 0.5 mM MgCl<sub>2</sub>. The proteins of this nuclear fraction were extracted as described above.

The protein concentration was determined by the Bradford method [28]. Then, 20 µg of cellular and 50 µg of nuclear protein were used for SDS-PAGE analysis according to Laemmli et al. [29] and transferred to Hybond-C extra nitrocellulose membrane (Amersham plc, Buckinghamshire, UK). Non-specific epitopes were masked, exposing membranes to 5% freeze-dried fat-free milk in TBS-T for 1 hour. Primary antibodies (see Table 1) were incubated for 2 hours. After washings, the blots were incubated with the secondary antibody: peroxidase-conjugated swine anti-rabbit and rabbit anti-mouse (DAKO, Clostrup, Denmark) 1:2,000, or Peroxidase Horse Anti-Goat IgG (H+L; Vector Laboratories) 1:10,000 for 1 hour. Subsequently, the blots were washed, and the signal was detected by enhanced chemiluminescent ECL reagent (Amersham) according to the manufacturer's protocol. The blots were visualized on Super RX medical X-ray film (Fujifilm Corporation, Tokyo, Japan) and the bands quantitated by Kodak imaging software (Eastman Kodak Company, US). The protein expression was normalized to the house-keeping protein gamma-tubulin, and additionally to mitochondrial content (NAO result) in the case of the mitochondrial proteins.

### Glucose and lactate test

The glucose consumption and lactate production were measured from culture media of the cell proliferation test and results were normalized with concomitant cell number. Glucose and lactate levels were analysed using the enzymatic-amperometric method and chip-sensor technology (Biosen C-line Sport, EKF Diagnostic, Magdeburg, Germany).

**Table 1. List of primary antibodies and dilutions used in Western blot.**

Antibody	Dilution	Host	Manufacturer
ATP5a	1:4000	Mouse monoclonal	Abcam, #MS502
β-actin	1:5000	Mouse monoclonal	Sigma, #A5316
β-catenin	1:400	Mouse monoclonal	Transduction Laboratories, BD Biosciences, #610153
Connexin 43	1:1000	Rabbit polyclonal	Sigma, #C6219
αD15C (anti-DAFIT)	1:160	Rabbit polygonal	Custom made [5]
E-cadherin	1:1000	Rabbit polyclonal	Santa Cruz, #sc-7870
γ-tubulin	1:4000	Mouse monoclonal	Sigma, #T5326
GFP	1:10000	Mouse monoclonal	Zymed, #33–2600
Hif1α	1:1000	Mouse monoclonal	Abcam, #10625, ab8366
Histone H1	1:500	Mouse monoclonal	Santa Cruz, #sc-8030
HSP60	1:600	Mouse monoclonal	Sigma, #4149
Integrin α2	1:200	Mouse monoclonal	Santa Cruz, #sc-13546
N-cadherin	1:1000	Mouse monoclonal	Sigma, #C2542
NDUFS3	1:10000	Mouse monoclonal	Abcam, # 14711
PGC1α	1:3000	Rabbit polyclonal	Millipore, #516557
RhoA	1:200	Mouse monoclonal	Santa Cruz, #sc-418
Sirt3	1:400	Goat polyclonal	Abcam, #118334
Smooth muscle actin	1:200	Mouse monoclonal	Sigma, #A5228
VDAC1/Porin	1:1000	Mouse monoclonal	Nordic BioSite, #MSA03
Vimentin	1:200	Goat polyclonal	Millipore, #AB1620
Zo-1	1:300	Mouse monoclonal	Invitrogen, #339100

doi:10.1371/journal.pone.0131990.t001

## Oncomine data analysis

We used the Oncomine Cancer Genomics Data Analysis tool [30] to mine *Usmg5* copy number profiles in a large subset of carcinomas and cancer cell lines [31–48]. In the dataset information of cancers both significant differences ( $p \leq 0.05$ ) and fold changes ( $\geq 1$ ) were reported. The number of DNA copies ( $= 2^*(2^{\wedge}y\text{-axis value})$ ) were calculated as advised in Oncomine instructions.

## Statistical analysis

Comparisons between cell lines were performed by using Mann-Whitney U test.


## Results

For the sake of simplicity, from now on we will call “control cells” the cells transfected with empty pIRES2-EGFP vector and “DAFIT cells” the ones over-expressing transgenic DAFIT. The transgene is co-transcribed with a cytosolic GFP reporter, independent from fusion protein.

### Mitochondrial mass, mtDNA and DAFIT over-expressing cells

As DAFIT was reported a Fo subunit of H<sup>+</sup>-ATP synthase, the immunofluorescence analysis of DAFIT cells showed clear co-localization of mitochondrial and DAFIT signals (Fig 1A). Importantly, we observed very few DAFIT-positive lysosomes. Knowing that mitochondria that are targeted for degradation (e.g. through mitophagy) would lead to a transient localization of DAFIT into lysotracker positive compartments, our results suggest a pure mitochondrial location of this protein.





**Fig 1. DAPIT over-expression decreased mitochondrial mass and mtDNA content in DAPIT cells.** (A) Representative confocal microscopy images of cells stained by Mitotracker and Lysotracker (100 nM, 10–30', 37°C) and anti-DAPIT antibody,  $\alpha$ D15C. (B) mRNA expression of the *Usmg5* by semi-quantitative RT-PCR. Protein levels estimated by Western blot of (C) DAPIT and (D) EGFP. (E) Mitochondrial mass was measured by flow cytometry of NAO stained cells (200nM, 30', 37°C). (F) Protein level of PGC1 $\alpha$  from nuclear extract. (G) mtDNA content by quantitative PCR. The error bars are S.D. and asterisks indicate: \* $p$ <0.05, \*\* $p$ <0.01.

doi:10.1371/journal.pone.0131990.g001

In this study, we emphasize the comparison of DAPIT cells to control ones due to vector transduction and following culture conditions. For assuring our cell model, the mRNA and protein level and mitochondrial mass from HEK293T cells are also reported. As mitochondrial mass is sensitive to  $H^+$ -ATP synthase impairments [23,49,50], the concomitant differences in mass between cell lines are normalized into reported mitochondrial parameters.

The expression of transgene was controlled by reverse transcriptase-PCR (RT-PCR) and Western blot analysis. DAPIT cells presented higher level of *Usmg5* messenger RNA compared to the HEK293T and control cells (Fig 1B) demonstrating the functionality of the DAPIT construct.

The expression of DAPIT protein in the three cell lines is shown in Fig 1C. DAPIT expression was slightly decreased in control cells (vehicle) as compared to HEK293T cells. A mild but not significant increase was seen between HEK293T and DAPIT cells, but significantly higher expression was observed in DAPIT than in control cells ( $p$ <0.05). The green fluorescent protein expression appeared lower in DAPIT cells (Fig 1D) indicating that translation from the 5' RNA CAP is more efficient than internal ribosome entry, as previously reported [51].

In order to study the effect of DAPIT over-expression on mitochondrial physiology, we measured mitochondrial mass using the mitochondria specific dye NAO in HEK293T, control and DAPIT cell lines (Fig 1E). Mitochondrial mass in DAPIT cells was significantly lower than in control and HEK293T cells, while it was intermediate in HEK293T cells.

To verify the mitochondrial mass in control and DAPIT cells, we measured mtDNA copy number and nuclear level of mitochondrial biogenesis regulating transcription factor PGC1 $\alpha$ . In line with NAO results, both the translocation of PGC1 $\alpha$  to the nuclei and the mtDNA content were decreased in DAPIT cells (Fig 1F and 1G). These results indicate that mitogenesis is decreased in DAPIT cells.

## Metabolic activity of mitochondria


We next estimated the effect of DAPIT over-expression on mitochondrial protein transport, TCA cycle activity, respiratory chain activity in intact cells and oxygen consumption driven by complexes I, II and IV in permeabilized cells. The results are reported both at cellular level (S1 Fig) and in relation to mitochondrial content (NAO normalized results, Fig 2).

The expression of VDAC1 (Fig 2A and 2M) and the activity of citrate synthase (Fig 2B) were increased significantly upon DAPIT over-expression ( $p = 0.001$  and  $0.05$ , respectively). These results could indicate increased transport or reduced turn-over of cytosolic substrates suitable for enhanced oxidation by TCA cycle, thereby facilitating the demands of respiratory chain.

The protein expression of C1 subunit NDUFS3 ( $p = 0.004$ ) was increased in DAPIT cells (Fig 2C and 2M). In addition, both the oxygen consumption from complexes I, II and IV in digitonin-permeabilized cells and respiration of intact cells (Fig 2D and 2E) were significantly increased ( $p = 0.044, 0.000, 0.002, 0.000$ ), respectively. However, the expression of F<sub>1</sub> complex subunit ATP5a was unaltered (Fig 2F and 2M) suggesting that enhanced oxygen consumption seen in DAPIT cells is not due to increase in CV content. Instead, the changes in respiratory chain function are supported by unchanged expression of Sirt3 (Fig 2G and 2M), a modulator of the activity of metabolic enzymes. In addition, DAPIT cells exhibit increased basal and maximal respiration ( $p = 0.003$  and  $0.004$ , respectively) (Fig 2H) and decreased activity of ATP synthase ( $p = 0.005$ ) (Fig 2I). These results suggest enhanced substrate availability and increased activity of TCA cycle, efficient respiration, active coupling but decreased H<sup>+</sup>-ATP synthase activity in DAPIT cells. Accordingly, the membrane potential ( $p = 0.001$ ) and superoxide ( $p = 0.001$ ) levels were increased (Fig 2J and 2K). When assessed at cell level (S1 Fig), respiration and TCA cycle activity remained unchanged between cell lines but VDAC1 expression, CV activity, membrane potential and superoxide showed the same changes as when normalized to mitochondrial mass. Taken together, these results suggest the saturation of respiratory chain due to DAPIT over-expression. The protein level of HSP60 increased significantly ( $p = 0.009$ ) in DAPIT cells (Fig 2L and 2M), indicative of an appropriate maintenance of the mitochondrial proteins.

## Nuclear proteins

We observed increased nuclear translocation of the Hif1 $\alpha$  transcription factor in DAPIT cells (Fig 3A and 3C). We also observed an increased protein expression of nuclear  $\beta$ -catenin (Fig 3B and 3C) and relocation of E-cadherin from cell junctions to the cytosol in DAPIT cells (Fig 3D, upper panel). Altogether, these results suggest major remodeling of cellular functions in response to DAPIT over-expression, since Hif1 $\alpha$  and  $\beta$ -catenin level are known to be involved in cellular dedifferentiation [52].




**Fig 2. Mitochondrial activity in DAPIT over-expression (relative to mitochondrial mass (NAO)).** (A) Protein level of VDAC1 by Western blot of cellular lysates. (B) Citrate synthase activity was measured by spectrophotometric analysis from protein extracts of control and DAPIT cells. (C) Protein level of NDUFS3. (D) Inhibitor-sensitive oxygen consumption of complexes I, II, IV and (E) complex V in digitonin-permeabilized and intact cells. Protein level of (F) ATP5a and (G) Sirt3. (H) Basal and maximal respiration by oxygen consumption of living cells. (I) Spectrophotometric analysis applied for measuring CV activity in backward direction using lactic dehydrogenase and pyruvate kinase as coupling enzymes. Mitochondrial (J) membrane potential and (K) superoxide levels measured by flow cytometry of TMRM (200nM, 30', 37°C) and Mitosox (2.5 μM, 45', 37°C) stained cells. (L) Protein expression of HSP60. (M) Representative immunoblots. The error bars are S.D. and asterisks indicate: \*p < 0.05, \*\*p < 0.01 and \*\*\*p < 0.001.

doi:10.1371/journal.pone.0131990.g002

## Morphological analysis of cell junction and adhesion proteins in DAPIT over-expressing cells

The over-expression of DAPIT induced changes in cell morphology, from a regular cuboidal epithelial-like (control cells) to an irregularly sized and shaped morphology (DAPIT cells) with decreased intercellular separation, showing a polygonal, sheet-like appearance but unaffected cell projections (Fig 3D, lower panel), thereby suggesting an epithelial to mesenchymal transition (EMT).




**Fig 3. DAPIT over-expression regulates nuclear translocation of Hif1 $\alpha$  and  $\beta$ -catenin leading to morphological changes.** Nuclear protein level of (A) Hif1 $\alpha$  and (B)  $\beta$ -catenin by Western blot. (C) Representative immunoblots. (D) Immunofluorescence of E-cadherin (upper panel, 100x magnification) and microscope view of living control and DAPIT cells (lower panel, 20x magnification). The error bars are S.D. and asterisk indicates \*p < 0.05.

doi:10.1371/journal.pone.0131990.g003

Due to morphological changes in DAPIT cells, we investigated the expression of several cell junction and adhesion proteins (Fig 4). Protein levels of E-cadherin decreased significantly (Fig 4A and 4I), while N-cadherin, Connexin 43, ZO-1, Vimentin, Integrin  $\alpha$ 2, and their modulator RhoA GTPase were all increased (Fig 4B–4G and 4I). We also observed increased (although non-significant) expression of the SMA (Fig 4H and 4I). Interestingly, such pattern of expression is reminiscent of the EMT observed, for example, in embryogenesis, wound healing and cancer.

### Cell growth, mortality, migration and adhesion

In order to study the effect of DAPIT over-expression on cell physiology and to clarify the consequences of the EMT-like phenotype, we examined cell growth, mortality, cell cycle, migration and adhesion capacity (Fig 5). According to hemocytometer calculation, DAPIT cells showed slower growth during the active growing phase (Fig 5A, days 1–3). Since the mortality rate, measured at day 2, was not altered (Fig 5B), we attribute the slower cell proliferation to a



**Fig 4. Modification in cell junction and adhesion proteins correspond to EMT-like changes in DAPIT cells.** (A-H) Modulation of cell junction proteins and RhoA. Protein expression by Western blot in 20µg of cell lysate. (I) Representative immunoblots. The error bars are S.D. and asterisks indicates \*\*p<0.01.


doi:10.1371/journal.pone.0131990.g004

reduced proliferation rather than increased cell death. To test this premise, we followed the cell cycle in synchronized cells. After withdrawal of thymidine, DAPIT cells entered the G1 phase approximately four hours later than control cells (seen at time point 4 h) (Fig 5C, dark grey). This retardation results also significant difference in S phase from 12 h on (light grey) and in G2 (medium grey) at 4 h onwards, thereby confirming the slower growth of DAPIT cells.

The unexpected decreased migration capacity (Fig 5D) of DAPIT cells is in contradiction with EMT and suggests a suppressive trait. The attachment capacity of the cells remained unchanged, whereas cell detachment was enhanced (Fig 5E and 5F), indicating adhesion characteristics typical of EMT.

### Glucose consumption and lactate production

The miss-functional ATP-synthase, reduced growth and HIF1α stabilization in DAPIT cells suggested a metabolic shift from aerobic respiration to glycolysis. Therefore, we measured, in parallel, glucose consumption and lactate production in DAPIT cells. As we anticipated, DAPIT cells consumed more glucose and produced more lactate during the exponential stage of their growth at days 1–3 (Fig 5G and 5H). Cell growth reached a plateau at day 4, and this was associated with a decreased glucose consumption and lactate production, a metabolic switch attributable to cell quiescence (see Valcourt et al. [53] for a review).



**Fig 5. Characteristics of cell behaviour and metabolism of DAPIT over-expressing cells.** (A) Cell proliferation by cell counting. (B) Mortality rate at day two of culture. (C) Flow cytometric analysis of cell cycle progression after double thymidine synchronization of the cells. (D) Cell migration by scratch wound assay. Cell adhesion capacity; (E) attachment measured by PMS/MTS test and (F) detachment according to migration test. (G) Glucose consumption and (H) lactate production measured in parallel from the culture medium of the cell proliferation test. The error bars are S.D. and asterisks indicate: \* $p < 0.05$  and \*\* $p < 0.01$ .

doi:10.1371/journal.pone.0131990.g005

### *Usmg5* copy number in cancers

Since DAPIT over-expression induced EMT and glycolytic switch in HEK293T cells, we tested if DAPIT is over-presented in cancers. The Oncomine Cancer Genomics database revealed a duplication (4 copies) of *Usmg5* copy number in a large panel of cancers (Table 2). *Usmg5* was ranked within 10% of top genes duplicated in various brain, pancreas and liver cancers, within 15% in sarcomas, kidney, lung and gastric cancers, and within approximately 20% in leukemia, lymphoma, and breast- and ovarian cancers. These data strongly suggest a role for DAPIT over-expression in cancers.

### Discussion

The OXPHOS system comprises five multi-subunit enzymes known as complexes I, II, III, IV and V. The electron transfer through complexes I-IV is coupled to proton translocation across the inner membrane. This results transmembrane electrochemical potential which is converted into chemical energy in the form of ATP by  $H^+$ -ATP synthase (CV).

**Table 2. Cancers expressing increased genomic *Usmg5* copy number in Oncomine cancer genomics database.**

Classification	Cancer type	DNA copy number	*Gene rank %	Oncomine datasets
Brain	Astrocytoma	4,40	1	Beroukhim Brain [31]
	Astrocytoma	4,50	3	TCGA Brain 2 [N/A]
	Astrocytoma	4,36	4	Kotliarov Brain [32]
	Astrocytoma	4,07	12	Northcott Brain 4 [33]
	Head and Neck Cancer Cell Line	4,13	2	Beroukhim Multi-cancer [34]
	Head and Neck Cancer	4,11	5	Beroukhim Multi-cancer [34]
	Head and Neck Cancer	4,13	24	Barretina CellLine 2 [35]
	Mixed Glioma	4,89	1	TCGA Brain 2 [N/A]
	Oligodendroglial Tumor	4,73	2	Kotliarov Brain [32]
	Oligodendroglial Tumor	5,07	3	TCGA Brain 2 [N/A]
	Oligodendroglial Tumor	4,29	7	Beroukhim Brain [31]
Pancreas	Pancreatic Cancer	4,19	6	Barretina CellLine 2 [35]
Liver	Liver Cancer	4,33	4	Rothenberg CellLine [38]
	Liver Cancer	4,18	7	Barretina CellLine 2 [35]
	Liver Cancer Precursor	4,10	29	Chiang Liver 2 [46]
Sarcoma	Dedifferentiated Liposarcoma	4,12	9	Barretina Sarcoma 2 [37]
	Myxoid/Round Cell Liposarcoma	4,12	15	Barretina Sarcoma 2 [37]
	Sarcoma	4,12	8	Barretina CellLine 2 [35]
	Sarcoma	4,12	12	Wooster CellLine 2 [N/A]
	Sarcoma	4,10	13	Rothenberg CellLine [38]
	Sarcoma Cell Line	4,14	24	Beroukhim Multi-cancer [34]
Kidney	Kidney Cancer	4,67	2	Neale Multi-cancer 2 [43]
	Kidney Cancer	4,20	12	Barretina CellLine 2 [35]
	Hereditary Clear Cell Renal Cell Carcinoma	4,07	26	Beroukhim Renal 2 [47]
Lung	Non-Small Cell Lung Carcinoma	4,13	10	Weiss Lung [40]
	Non-Small Cell Lung Carcinoma	4,18	12	TCGA Lung 2 [N/A]
Gastric	Gastric Adenocarcinoma	4,06	14	Deng Gastric [36]
	Gastric Mixed Adenocarcinoma vs. Normal	4,10	15	Deng Gastric [36]
	Gastrointestinal Stromal Tumor	4,40	17	Barretina Sarcoma 4 [37]
	Colon Adenocarcinoma	4,06	14	TCGA Colorectal 2 [N/A]
	Colorectal Cancer	4,13	13	Rothenberg CellLine [38]
	Colorectal Cancer	4,07	18	Barretina CellLine 2 [35]
	Colorectal Cancer	4,28	13	Jaiswal Multi-cancer [39]
	Leukemia	Leukemia	4,46	5
Leukemia	Refractory Anemia with Excess Blasts-1 vs. Normal	4,13	13	Yoshida Leukemia [44]
	Chronic Myelomonocytic Leukemia-1 vs. Normal	4,12	14	Yoshida Leukemia [44]
	Leukemia Cell Line	4,17	20	Beroukhim Multi-cancer [34]
	Plasma Cell Leukemia	4,09	21	Chapman Myeloma 2 [45]
	Breast	Mixed Lobular and Ductal Breast Carcinoma	4,11	7
Papillary Breast Carcinoma		4,08	11	TCGA Breast 2 [N/A]
Mucinous Breast Carcinoma		4,08	20	Curtis Breast 2 [42]
Lobular Breast Carcinoma		4,07	23	TCGA Breast 2 [N/A]
Ductal Breast Carcinoma in Situ		4,06	24	Curtis Breast 2 [42]
Ovarian	Ovarian Cancer	4,09	16	Beroukhim Multi-cancer [34]
	Endometrial Endometrioid Adenocarcinoma vs. Normal	4,10	17	TCGA Endometrium [N/A]
	Endometrial Serous Adenocarcinoma vs. Normal	4,16	29	TCGA Endometrium [N/A]

(Continued)

Table 2. (Continued)

Classification	Cancer type	DNA copy number	*Gene rank %	Oncomine datasets
Lymphoma	Lymphoma	4,15	21	Wooster CellLine 2 [N/A]
	Lymphoma	4,08	28	Barretina CellLine 2 [35]
Other	Oral Cavity Squamous Cell Carcinoma vs. Normal	4,03	48	Peng Head-Neck 2 [48]

N/A indicating not available.

\* Indicating % of top genes duplicated, within which *Usmg5* was ranked.

doi:10.1371/journal.pone.0131990.t002

DAPIT has been shown to be a structural component of H<sup>+</sup>-ATP synthase and its deletion resulted in the loss of H<sup>+</sup>-ATP synthase [2–5]. As DAPIT mRNA and/or protein levels are increased in various diseases [6–8, 10–14] we hypothesized that in addition to its structural role, DAPIT could also be a regulatory component of H<sup>+</sup>-ATP synthase. In consequence, DAPIT up-regulation could lead to both structural changes and alteration in respiratory chain regulation. In the present study, we stably transfected DAPIT into HEK293T cells. The strategy we used permits both the transgene and an EGFP reporter to be translated from a single bicistronic mRNA without formation of a fusion protein. The DNA sequence of the DAPIT transgene appeared unaltered and the expression of the protein was confirmed. We emphasized the effect of DAPIT over-expression on mitochondrial level by normalizing the reported mitochondrial parameters with concomitant mass. Accordingly, DAPIT up-regulation did not alter the mitochondrial H<sup>+</sup>-ATP synthase levels in terms of the expression of ATP5a (a subunit of the H<sup>+</sup>-ATP synthase enzymatic channel). Still, DAPIT cells showed an increased basal respiration and inhibitor-sensitive oxygen consumption of complexes I, II and IV, but decreased activity of H<sup>+</sup>-ATP-synthase. This result is in line with cellular increase in lactate production. Therefore, we suggest that increased maximal respiration is due to increased capacity of complexes I-IV. Since mitochondrial mass was decreased, we conclude that DAPIT positively modulates respiration. In agreement with this hypothesis, we observed increased membrane potential together with citrate synthase activity and VDAC1 expression, an issue suggesting increased availability and use of respiratory chain substrates. As DAPIT cells are glycolytic, these may have altered their catabolic balance in order to fuel the respiration. Accordingly, an accumulation of superoxide production per mitochondria and DAPIT cell was also observed. Interestingly, it was recently reported that intracellular balance of respiratory substrates contribute to the cell decision between differentiation and stemness [54].

Most of the energy needed by human cells is provided by mitochondria in the form of ATP through oxidative phosphorylation. Mitochondrial adenosine triphosphate (ATP) synthesis, while essential to maintain homeostasis, is sensitive to oxidative damages and other cellular injuries [49], and alterations of H<sup>+</sup>-ATP synthase biogenesis increases ROS production while decreasing energy production [55]. ROS damages could disrupt mitochondrial integrity and lead to apoptosis or necrosis, depending on cellular energy status. Regardless of increased mitochondrial respiration and good coupling, the activity of H<sup>+</sup>-ATP-synthase was decreased in DAPIT cells. This decrease could be due to diminished number of H<sup>+</sup>-ATP-synthase complexes in mitochondrial inner membrane, the down-regulation of its enzymatic/hydrolytic activity or both. The decreased H<sup>+</sup>-ATP-synthase activity is well documented in human tumors where the Inhibitory Factor 1 (IF1) of H<sup>+</sup>-ATP-synthase mediates the metabolic shift of cancer cells to aerobic glycolysis with mitochondrial hyperpolarization and subsequent production of superoxide radical [56,57], the mitochondrial characteristics also seen in DAPIT cells. Moreover, the regulated degradation of IF1 controlled energy metabolism during osteogenic



differentiation of human mesenchymal stem cells by hindering their self-renewal, but favouring differentiation [58]. These reported studies clarify a mito-cellular mechanism by which the activity of H<sup>+</sup>-ATP-synthase is physiologically regulated in stemness, differentiation and cancer, process where DAPIT over-expression might be involved in. Altogether, these results fit with the idea that DAPIT over-expression accelerates mitochondrial respiration although, or because, inactivating H<sup>+</sup>-ATP synthase.

Cells can adapt to mitochondrial dysfunctions and energy depletion by regulating mitochondrial biogenesis [49,50]. We observed significant decrease in mtDNA level due to inactivation of mitogenesis in impaired H<sup>+</sup>-ATP-synthase DAPIT cells.

Hif1 induction is reported to shift aerobic cellular metabolism to glycolysis [15–17,59]. Accordingly, translocation of Hif1a to the nucleus was induced in DAPIT cells, and both glucose consumption and lactate production were significantly enhanced. Interestingly, these changes are reminiscent of the Warburg effect observed in many cancers and stem cells.

Hif1 $\alpha$  stabilization is also involved in EMT, which is a process of epithelial cells losing cell-cell junctions and baso-apical polarity while acquiring plasticity, mobility, invasive capacity, stem-like characteristics and resistance to apoptosis [60–62]. This cell biology program is active in embryos, fibrosis, wound healing and in promoting metastasis in cancer. In addition to Hif1a, the Wnt/ $\beta$ -catenin pathway signalling also controls EMT upon hypoxic stress in cancer [60,61]. One of the hallmarks of EMT in cancer is the disappearance of E-cadherin from the cellular membrane and its replacement with N-cadherin. Several key transcription factors regulating E-cadherin expression and/or the fate of other epithelial molecules are direct or indirect transcriptional targets of the canonical Wnt pathway [61]. Accordingly, we saw E-cadherin shift to N-cadherin (and regulation of various other proteins) in DAPIT cells and nuclear expression of  $\beta$ -catenin indicating activation of Wnt signalling. All these molecular findings provide evidence that supports the involvement of DAPIT over-expression in altered mitochondrial function in cancer and stemness.

EMT resembling change in DAPIT cells induced transformation of regular cuboidal epithelial-like cells into irregularly sized and shaped cells showing a polygonal, tightly packed, sheet-like appearance with short projections reminiscent of mesenchymal-like cells. However, in contrast to mesenchymal cells, DAPIT cells presented an unexpected decrease in migration capacity. This suggests that some of the defects caused by DAPIT over-expression suppressed the normally improved migratory capacity of mesenchymal-like cells. However, if cell adhesion was unaltered, dissociation from the surface was more frequent.

DAPIT cells grew slower while presenting normal viability. We studied the cell-cycle progression by thymidine synchronization and found that DAPIT cells were arrested in G1. Previously it was shown that the activation of Hif1 $\alpha$  (which occurred in DAPIT cells) in embryonic stem cells and colon cancer cells under hypoxia inhibited transcriptional activity of  $\beta$ -catenin resulting in G1 arrest [63,64]. Taken together, the physiological properties of DAPIT cells resemble an EMT-like phenotype with mitochondrial impairment leading to glycolytic metabolism, decreased cell proliferation and migration, and an increase in cell dissociation from the surface, the issues active in varying conditions of cancer and stem cells. Interestingly, searching in the Oncomine cancer genomics database revealed a duplication in *Usmg5* copy number in various cancers (Table 2). This was ranked within 15% of top of duplicated genes in classified brain, pancreas, liver, sarcoma, kidney, lung, gastric, leukemia, breast and ovarian cancers. Despite the link between DAPIT and the tumorigenic capacity has not been sufficiently demonstrated, this result strengthens a correlative involvement of DAPIT in cancer and suggests a possible oncogenic function for it.

In summary, we have characterized the effect of a stable over-expression of DAPIT in a cell culture model; at the level of morphology, molecular biology, metabolic homeostasis and cell

behavior. The over-expression of DAPIT in HEK293T cells impaired mitochondria promoting the activation of Hif1 $\alpha$  and Wnt/ $\beta$ -catenin signaling, which resulted in a shift of aerobic metabolism to more glycolytic direction and in cell dedifferentiation resembling EMT. We suggest that DAPIT over-expression couples changes in mitochondrial metabolism to physiological and pathophysiological activities at the cellular level, possibly including cancer.

## Supporting Information

**S1 Fig. Mitochondrial metabolism (activity) at cellular level.** Protein levels estimated by Western blot of (A) DAPIT and (B) VDAC. (C) Citrate synthase activity. (D) Protein level of NDUFS3. Inhibitor-sensitive oxygen consumption of (E) complexes I, II, IV and (F) complex V in digitonin-permeabilized and intact cells. Protein level of (G) ATP5a and (H) Sirt3. (I) Basal and maximal respiration. (J) H<sup>+</sup>-ATP synthase activity measured by spectrophotometric analysis. Mitochondrial (K) membrane potential and (L) superoxide levels at cellular level measured by flow cytometry of TMRM (200nM, 30', 37°C) and MitoSox (2,5  $\mu$ M, 45', 37°C) stained cells. (M) Protein level of HSP60. Representative immunoblots are shown in [Fig 2M](#). The error bars are S.D. and asterisks indicate: \*\*p<0.01. (PDF)

## Acknowledgments

The authors would like to thank Cristina Nadalutti, Kaisa Teittinen, Mervi Matero and Risto Puurtinen for technical help and useful discussions.

## Author Contributions

Conceived and designed the experiments: H. Kontro H. Kainulainen. Performed the experiments: H. Kontro GC PR ED. Analyzed the data: H. Kontro GC PR ED. Contributed reagents/materials/analysis tools: H. Kontro ED PR H. Kainulainen. Wrote the paper: H. Kontro GC PR ED H. Kainulainen. Set up and optimized the method for HEK293T cells used in membrane potential and superoxide analysis: GC.

## References

1. Paivarinne H, Kainulainen H. DAPIT, a novel protein down-regulated in insulin-sensitive tissues in streptozotocin-induced diabetes. *Acta Diabetol.* 2001; 38(2):83–86. PMID: [11757806](#)
2. Chen R, Runswick MJ, Carroll J, Fearnley IM, Walker JE. Association of two proteolipids of unknown function with ATP synthase from bovine heart mitochondria. *FEBS Lett.* 2007; 581(17):3145–3148. doi: [10.1016/j.febslet.2007.05.079](#) PMID: [17570365](#)
3. Meyer B, Wittig I, Trifilieff E, Karas M, Schagger H. Identification of two proteins associated with mammalian ATP synthase. *Mol Cell Proteomics.* 2007; 6(10):1690–1699. doi: [10.1074/mcp.M700097-MCP200](#) PMID: [17575325](#)
4. Lee J, Ding S, Walpole TB, Holding AN, Montgomery MG, Fearnley IM, et al. Organisation of Subunits in the Membrane Domain of the Bovine F-ATPase Revealed by Covalent Cross-linking. *J Biol Chem.* 2015 Apr 7. doi: [10.1074/jbc.M115.645283](#)
5. Ohsakaya S, Fujikawa M, Hisabori T, Yoshida M. Knockdown of DAPIT (diabetes-associated protein in insulin-sensitive tissue) results in loss of ATP synthase in mitochondria. *J Biol Chem.* 2011; 286(23):20292–20296. doi: [10.1074/jbc.M110.198523](#) PMID: [21345788](#)
6. Kontro H, Hulmi JJ, Rahkila P, Kainulainen H. Cellular and tissue expression of DAPIT, a phylogenetically conserved peptide. *Eur J Histochem.* 2012; 56(2):e18. doi: [10.4081/ejh.2012.18](#) PMID: [22688299](#)
7. Zhang L, Yu C, Vasquez FE, Galeva N, Onyango I, Swerdlow RH, et al. Hyperglycemia alters the schwann cell mitochondrial proteome and decreases coupled respiration in the absence of superoxide production. *J Proteome Res.* 2010; 9(1):458–471. doi: [10.1021/pr900818g](#) PMID: [19905032](#)

8. McFarland MA, Ellis CE, Markey SP, Nussbaum RL. Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. *Mol Cell Proteomics*. 2008; 7(11):2123–2137. doi: [10.1074/mcp.M800116-MCP200](https://doi.org/10.1074/mcp.M800116-MCP200) PMID: [18614564](https://pubmed.ncbi.nlm.nih.gov/18614564/)
9. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: Archive for functional genomics data sets—update. *Nucleic Acids Res*. 2013; 41(Database issue):D991–5. doi: [10.1093/nar/gks1193](https://doi.org/10.1093/nar/gks1193) PMID: [23193258](https://pubmed.ncbi.nlm.nih.gov/23193258/)
10. Lee CH, Bang SH, Lee SK, Song KY, Lee IC. Gene expression profiling reveals sequential changes in gastric tubular adenoma and carcinoma in situ. *World J Gastroenterol*. 2005; 11(13):1937–1945. PMID: [15800983](https://pubmed.ncbi.nlm.nih.gov/15800983/)
11. Selga E, Morales C, Noe V, Peinado MA, Ciudad CJ. Role of caveolin 1, E-cadherin, enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells. *BMC Med Genomics*. 2008; 1:35-8794-1-35. doi: [10.1186/1755-8794-1-35](https://doi.org/10.1186/1755-8794-1-35)
12. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. *BMC Med Genomics*. 2009; 2:34-8794-2-34. doi: [10.1186/1755-8794-2-34](https://doi.org/10.1186/1755-8794-2-34)
13. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. *Mol Cell*. 2007; 26(5):745–752. doi: [10.1016/j.molcel.2007.05.010](https://doi.org/10.1016/j.molcel.2007.05.010) PMID: [17540599](https://pubmed.ncbi.nlm.nih.gov/17540599/)
14. Koza RA, Nikonova L, Hogan J, Rim JS, Mendoza T, Faulk C, et al. Changes in gene expression foreshadow diet-induced obesity in genetically identical mice. *PLoS Genet*. 2006; 2(5):e81. doi: [10.1371/journal.pgen.0020081](https://doi.org/10.1371/journal.pgen.0020081) PMID: [16733553](https://pubmed.ncbi.nlm.nih.gov/16733553/)
15. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. *Nat Rev Cancer*. 2011; 11(2):85–95. doi: [10.1038/nrc2981](https://doi.org/10.1038/nrc2981) PMID: [21258394](https://pubmed.ncbi.nlm.nih.gov/21258394/)
16. Wallace DC. Mitochondria and cancer. *Nat Rev Cancer*. 2012; 12(10):685–698. doi: [10.1038/nrc3365](https://doi.org/10.1038/nrc3365) PMID: [23001348](https://pubmed.ncbi.nlm.nih.gov/23001348/)
17. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. *Mol Cell*. 2012; 48(2):158–167. doi: [10.1016/j.molcel.2012.09.025](https://doi.org/10.1016/j.molcel.2012.09.025) PMID: [23102266](https://pubmed.ncbi.nlm.nih.gov/23102266/)
18. Wheaton WW, Chandel NS. Hypoxia. 2. hypoxia regulates cellular metabolism. *Am J Physiol Cell Physiol*. 2011; 300(3):C385–93. doi: [10.1152/ajpcell.00485.2010](https://doi.org/10.1152/ajpcell.00485.2010) PMID: [21123733](https://pubmed.ncbi.nlm.nih.gov/21123733/)
19. Sullivan LB, Martinez-Garcia E, Nguyen H, Mullen AR, Dufour E, Sudarshan S, et al. The proto-oncogene metabolite fumarate binds glutathione to amplify ROS-dependent signaling. *Mol Cell*. 2013; 51(2):236–248. doi: [10.1016/j.molcel.2013.05.003](https://doi.org/10.1016/j.molcel.2013.05.003) PMID: [23747014](https://pubmed.ncbi.nlm.nih.gov/23747014/)
20. Huang JY, Hirschev MD, Shimazu T, Ho L, Verdin E. Mitochondrial sirtuins. *Biochim Biophys Acta*. 2010; 1804(8):1645–1651. doi: [10.1016/j.bbapap.2009.12.021](https://doi.org/10.1016/j.bbapap.2009.12.021) PMID: [20060508](https://pubmed.ncbi.nlm.nih.gov/20060508/)
21. Hallows WC, Lee S, Denu JM. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. *Proc Natl Acad Sci U S A*. 2006; 103(27):10230–10235. doi: [10.1073/pnas.0604392103](https://doi.org/10.1073/pnas.0604392103) PMID: [16790548](https://pubmed.ncbi.nlm.nih.gov/16790548/)
22. Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CF, Steegborn C. Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. *J Mol Biol*. 2008; 382(3):790–801. doi: [10.1016/j.jmb.2008.07.048](https://doi.org/10.1016/j.jmb.2008.07.048) PMID: [18680753](https://pubmed.ncbi.nlm.nih.gov/18680753/)
23. Fukuoh A, Cannino G, Gerards M, Buckley S, Kazancioglu S, Scialo F, et al. Screen for mitochondrial DNA copy number maintenance genes reveals essential role for ATP synthase. *Mol Syst Biol*. 2014; 10(6):734. doi: [10.15252/msb.20145117](https://doi.org/10.15252/msb.20145117)
24. Cannino G, El-Khoury R, Pirinen M. Glucose modulates respiratory complex I activity in response to acute mitochondrial dysfunction. *J Biol Chem*. 2012; 287(46):38729–38740. doi: [10.1074/jbc.M112.386060](https://doi.org/10.1074/jbc.M112.386060) PMID: [23007390](https://pubmed.ncbi.nlm.nih.gov/23007390/)
25. Rustin P, Chretien D, Bourgeron T, Gérard B, Rötig A, Saudubray JM, et al. Biochemical and molecular investigations in respiratory chain deficiencies. *Clin Chim Acta*. 1994; 228(1):35–51. PMID: [7955428](https://pubmed.ncbi.nlm.nih.gov/7955428/)
26. Benit P, Goncalves S, Philippe Dassa E, Briere JJ, Martin G, Rustin P. Three spectrophotometric assays for the measurement of the five respiratory chain complexes in minuscule biological samples. *Clin Chim Acta*. 2006; 374(1–2):81–86. doi: [10.1016/j.cca.2006.05.034](https://doi.org/10.1016/j.cca.2006.05.034) PMID: [16828729](https://pubmed.ncbi.nlm.nih.gov/16828729/)
27. Teittinen KJ, Karkkainen P, Salonen J, Rönholm G, Korkeamäki H, Vihinen M, et al. Nucleolar proteins with altered expression in leukemic cell lines. *Leuk Res*. 2012; 36(2):232–236. doi: [10.1016/j.leukres.2011.06.038](https://doi.org/10.1016/j.leukres.2011.06.038) PMID: [21783252](https://pubmed.ncbi.nlm.nih.gov/21783252/)
28. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem*. 1976; 72:248–254. PMID: [942051](https://pubmed.ncbi.nlm.nih.gov/942051/)
29. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature*. 1970; 227(5259):680–685. PMID: [5432063](https://pubmed.ncbi.nlm.nih.gov/5432063/)

30. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: A cancer microarray database and integrated data-mining platform. *Neoplasia*. 2004; 6(1):1–6. PMID: [15068665](#)
31. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. *Proc Natl Acad Sci U S A*. 2007; 104(50):20007–20012. doi: [10.1073/pnas.0710052104](#) PMID: [18077431](#)
32. Kotliarov Y, Steed ME, Christopher N, Walling J, Su Q, Center A, et al. High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. *Cancer Res*. 2006; 66(19):9428–9436. doi: [10.1158/0008-5472.CAN-06-1691](#) PMID: [17018597](#)
33. Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. *Nature*. 2012; 488(7409):49–56. doi: [10.1038/nature11327](#) PMID: [22832581](#)
34. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. *Nature*. 2010; 463(7283):899–905. doi: [10.1038/nature08822](#) PMID: [20164920](#)
35. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature*. 2012; 483(7391):603–607. doi: [10.1038/nature11003](#) PMID: [22460905](#)
36. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. *Gut*. 2012; 61(5):673–684. doi: [10.1136/gutjnl-2011-301839](#) PMID: [22315472](#)
37. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. *Nat Genet*. 2010; 42(8):715–721. doi: [10.1038/ng.619](#) PMID: [20601955](#)
38. Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, et al. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. *Cancer Res*. 2010; 70(6):2158–2164. doi: [10.1158/0008-5472.CAN-09-3458](#) PMID: [20215515](#)
39. Jaiswal BS, Janakiraman V, Kljavin NM, Chaudhuri S, Stern HM, Wang W, et al. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. *Cancer Cell*. 2009; 16(6):463–474. doi: [10.1016/j.ccr.2009.10.016](#) PMID: [19962665](#)
40. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. *Sci Transl Med*. 2010; 2(62):62ra93. doi: [10.1126/scitranslmed.3001451](#)
41. Nikolsky Y, Sviridov E, Yao J, Dosymbekov D, Ustyansky V, Kaznacheev V, et al. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. *Cancer Res*. 2008; 68(22):9532–9540. doi: [10.1158/0008-5472.CAN-08-308](#) PMID: [19010930](#)
42. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature*. 2012; 486(7403):346–352. doi: [10.1038/nature10983](#) PMID: [22522925](#)
43. Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, et al. Molecular characterization of the pediatric preclinical testing panel. *Clin Cancer Res*. 2008; 14(14):4572–4583. doi: [10.1158/1078-0432.CCR-07-5090](#) PMID: [18628472](#)
44. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. *Nature*. 2011; 478(7367):64–69. doi: [10.1038/nature10496](#) PMID: [21909114](#)
45. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. *Nature*. 2011; 471(7339):467–472. doi: [10.1038/nature09837](#) PMID: [21430775](#)
46. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. *Cancer Res*. 2008; 68(16):6779–6788. doi: [10.1158/0008-5472.CAN-08-0742](#) PMID: [18701503](#)
47. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. *Cancer Res*. 2009; 69(11):4674–4681. doi: [10.1158/0008-5472.CAN-09-0146](#) PMID: [19470766](#)
48. Peng CH, Liao CT, Peng SC, Chen YJ, Cheng AJ, Juang JL, et al. A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma. *PLoS One*. 2011; 6(8):e23452. doi: [10.1371/journal.pone.002345](#) PMID: [21853135](#)
49. Piantadosi CA, Suliman HB. Redox regulation of mitochondrial biogenesis. *Free Radic Biol Med*. 2012; 53(11):2043–2053. doi: [10.1016/j.freeradbiomed.2012.09.014](#) PMID: [23000245](#)

50. Scarpulla RC, Vega RB, Kelly DP. Transcriptional integration of mitochondrial biogenesis. *Trends Endocrinol Metab.* 2012; 23(9):459–466. doi: [10.1016/j.tem.2012.06.006](https://doi.org/10.1016/j.tem.2012.06.006) PMID: [22817841](https://pubmed.ncbi.nlm.nih.gov/22817841/)
51. Stein I, Itin A, Einat P, Skaliter R, Grossman Z, Keshet E. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: Implications for translation under hypoxia. *Mol Cell Biol.* 1998; 18(6):3112–3119. PMID: [9584152](https://pubmed.ncbi.nlm.nih.gov/9584152/)
52. Czerwinska P, Kaminska B. Regulation of breast cancer stem cell features. *Contemp Oncol (Pozn).* 2015; 19(1A):A7–A15. doi: [10.5114/wo.2014.47126](https://doi.org/10.5114/wo.2014.47126)
53. Valcourt JR, Lemons JM, Haley EM, Kojima M, Demuren OO, Collier HA. Staying alive: Metabolic adaptations to quiescence. *Cell Cycle.* 2012; 11(9):1680–1696. doi: [10.4161/cc.19879](https://doi.org/10.4161/cc.19879) PMID: [22510571](https://pubmed.ncbi.nlm.nih.gov/22510571/)
54. Carey BW, Finley LW, Cross JR, Allis CD, Thompson CB. Intracellular alpha-ketoglutarate maintains the pluripotency of embryonic stem cells. *Nature.* 2015; 518(7539):413–416. doi: [10.1038/nature13981](https://doi.org/10.1038/nature13981) PMID: [25487152](https://pubmed.ncbi.nlm.nih.gov/25487152/)
55. Geromel V, Kadhom N, Cebalos-Picot I, Ouari O, Polidori A, Munnich A, et al. Superoxide-induced massive apoptosis in cultured skin fibroblasts harboring the neurogenic ataxia retinitis pigmentosa (NARP) mutation in the ATPase-6 gene of the mitochondrial DNA. *Hum Mol Genet.* 2001; 10(11):1221–1228. PMID: [11371515](https://pubmed.ncbi.nlm.nih.gov/11371515/)
56. Sanchez-Cenizo L, Formentini L, Aldea M, Ortega AD, García-Huerta P, Sánchez-Aragó M, et al. Up-regulation of the ATPase inhibitory factor 1 (IF1) of the mitochondrial H<sup>+</sup>-ATP synthase in human tumors mediates the metabolic shift of cancer cells to a Warburg phenotype. *J Biol Chem.* 2010; 285(33):25308–25313. doi: [10.1074/jbc.M110.146480](https://doi.org/10.1074/jbc.M110.146480) PMID: [20538613](https://pubmed.ncbi.nlm.nih.gov/20538613/)
57. Formentini L, Sanchez-Arago M, Sanchez-Cenizo L, Cuezva JM. The mitochondrial ATPase inhibitory factor 1 triggers a ROS-mediated retrograde prosurvival and proliferative response. *Mol Cell.* 2012; 45(6):731–742. doi: [10.1016/j.molcel.2012.01.008](https://doi.org/10.1016/j.molcel.2012.01.008) PMID: [22342343](https://pubmed.ncbi.nlm.nih.gov/22342343/)
58. Sanchez-Arago M, Garcia-Bermudez J, Martinez-Reyes I, Santacatterina F, Cuezva JM. Degradation of IF1 controls energy metabolism during osteogenic differentiation of stem cells. *EMBO Rep.* 2013; 14(7):638–644. doi: [10.1038/embor.2013.72](https://doi.org/10.1038/embor.2013.72) PMID: [23722655](https://pubmed.ncbi.nlm.nih.gov/23722655/)
59. Yang M, Soga T, Pollard PJ. Oncometabolites: Linking altered metabolism with cancer. *J Clin Invest.* 2013; 123(9):3652–3658. doi: [10.1172/JCI67228](https://doi.org/10.1172/JCI67228) PMID: [23999438](https://pubmed.ncbi.nlm.nih.gov/23999438/)
60. Talbot LJ, Bhattacharya SD, Kuo PC. Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. *Int J Biochem Mol Biol.* 2012; 3(2):117–136. PMID: [22773954](https://pubmed.ncbi.nlm.nih.gov/22773954/)
61. Valenta T, Hausmann G, Basler K. The many faces and functions of beta-catenin. *EMBO J.* 2012; 31(12):2714–2736. doi: [10.1038/emboj.2012.150](https://doi.org/10.1038/emboj.2012.150) PMID: [22617422](https://pubmed.ncbi.nlm.nih.gov/22617422/)
62. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. *J Clin Invest.* 2009; 119(6):1429–1437. doi: [10.1172/JCI36183](https://doi.org/10.1172/JCI36183) PMID: [19487819](https://pubmed.ncbi.nlm.nih.gov/19487819/)
63. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. *Nature.* 1998; 394(6692):485–490. doi: [10.1038/28867](https://doi.org/10.1038/28867) PMID: [9697772](https://pubmed.ncbi.nlm.nih.gov/9697772/)
64. Kaidi A, Williams AC, Paraskeva C. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. *Nat Cell Biol.* 2007; 9(2):210–217. doi: [10.1038/ncb1534](https://doi.org/10.1038/ncb1534) PMID: [17220880](https://pubmed.ncbi.nlm.nih.gov/17220880/)